**Opana® ER references**

Please note:

* Reference #2 is a database and is therefore not included.
* References #3 and #6 are only available in abstract form.

**References**

1. Opana® ER [package insert]. Malvern (PA): Endo Pharmaceuticals Inc.; 2014 Apr.
2. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Dec 8]. Available from: <http://www.thomsonhc.com/>.
3. Katz N, Rauck R, Ahdieh H, Ma T, Gerritsen van der Hoop R, Kerwin R, Podolsky G. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naïve patients with chronic low back pain (abstract). Curr Med Res Opin. 2007 Jan;23(1):117-28.
4. Hale ME, Ahdieh H, Ma T, Rauck R, for the Oxymorphone ER Study Group 1. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: A 12-week, randomized, double-blind, placebo-controlled study. The Journal of Pain. 2007 Feb;8(2): 175-84.
5. Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer. 2005;13:57-65.
6. Slatkin NE, Rhiner MI, Gould EM, Ma T, Ahdieh H. Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer (abstract). J Opioid Manag. 2010;6(3):181-91.
7. Kivitz A., Ma C., Ahdieh H., Galer BS. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clinical Therapeutics. 2006;38(3):352-64.
8. Ahdieh H, Ma T, Babul N, Lee D. Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty. Journal of Clinical Pharmacology. 2004;44:767-76.
9. Abandoned painkiller makes a comeback- here’s how the FDA let a widely abused opioid back on the market. [press release on the Internet]. Medpage. 2015 May 10 [cited 2015 Dec 13]. Available from: http://www.medpagetoday.com/Psychiatry/Addictions/51448.
10. FDA Statement: Original Opana ER Relisting Determination [press release on the internet]. Rockville (MD): Food and Drug Administration (US): 2013 May 10 [cited 2015 Dec 10]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm351357.
11. Abuse of Endo’s second-generation Opana ER formulation implicated in Indiana HIV epidemic. [press release on the Internet]. FiercePharma. 2015 Jun 16 [cited 2015 Dec 10]. Available from: <http://www.fiercedrugdelivery.com/story/abuse-endos-second-generation-opana-er-formulation-implicated-indiana-hiv-e/2015-06-16>.
12. FDA/CDER final response to Endo Pharmaceuticals Inc petition denial. Regulations.gov. Rockville (MD): Food and Drug Administration (US); 2013 May 10 [cited 2015 Dec 9]. Available from: <http://www.regulations.gov/#!documentDetail;D=FDA-2012-P-0895-0014>
13. U.S. Food and Drug Administration. Opioid Medications; Information on Opioid Medications. Silver Spring (MD): Food and Drug Administration; 2015 Nov 25. [cited 2015 Dec 3]. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm337066.htm.
14. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled Phase III study. The Journal of Pain. 2005 Jan;6(1):21-28.